Mood disorders are a leading cause of morbidity. Many patients experience treatment-resistant depression (TRD), and suicide rates are rising. Faster-acting and more effective antidepressant medications are needed. Four decades of research has transformed the use of ket-amine from an anesthetic to an outpatient treatment for major depressive disorder (MDD). Ketamine is a N-methyl-D-aspartate (NMDA) receptor antagonist and has been shown to rapidly improve mood symptoms and suicidal ideation by targeting the glutamate system directly.
Methods
We used the PubMed database to identify relevant articles published until September 1, 2020. We focused on meta-analyses, randomized controlled trials, and original observational studies. We included relevant studies for depression, MDD, TRD, bipolar disorder, anxiety, posttrau-matic stress disorder (PTSD), suicide, ketamine, and esketamine.
Results
Both racemic ketamine and esketamine have been shown to rapidly treat depression and suicidality. There is evidence that ketamine can be helpful for anxiety and PTSD; however, more research is needed. Intranasal esketamine has been FDA approved to treat depression.
Conclusions
This narrative review describes the evolution of ketamine to treat mood disorders and suicidality. We provide the evidence supporting recent developments using esketamine as well as unresolved issues in the field, such as dosing and safety.
Get full access to this article
View all access options for this article.
References
1.
FerrariAJCharlsonFJNormanRE. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med.2013; 10: e1001547.
2.
HeronM.Deaths: leading causes for2016. Natl Vital Stat Rep. 2018; 67: 1-77.
3.
RushAJFavaMWisniewskiSR. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials.2004; 25: 119-142.
4.
PacchiarottiIBondDJBaldessariniRJ. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry.2013; 170: 1249-1262.
5.
HashimotoK.Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci.2019; 73: 613-627.
6.
ReichDLSilvayG.Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth. 1989; 36: 186-197.
7.
BermanRMCappielloAAnandA. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry.2000; 47: 351-354.
8.
ZarateCAJr, SinghJB, CarlsonPJ, . A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry.2006; 63: 856-864.
9.
MurroughJWIosifescuDVChangLC. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry.2013; 170: 1134-1142.
10.
KishimotoTChawlaJMHagiK. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med.2016; 46: 1459-1472.
11.
NewportDJCarpenterLLMcDonaldWM. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry.2015; 172: 950-966.
12.
XuYHackettMCarterG. Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol.2016; 19: pyv124.
13.
FavaMFreemanM PFlynnM. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry.2020; 25: 1592-1603.
14.
NiciuMJShovestulBJJasoBA. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J Affect Disord.2018; 232: 310-315.
15.
GeorgeDGálvezVMartinD. Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. Am J Geriatr Psychiatry.2017; 25: 1199-1209.
16.
SuTPChenMHLiCT. Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology.2017; 42: 2482-2492.
17.
LallyNNugentACLuckenbaughDA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry.2014; 4: e469.
18.
ChiuCTScheuingLLiuG. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int J Neuropsychopharmacol.2014; 18: pyu102.
19.
CostiSSoleimaniLGlasgowA. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. Neuropsychopharmacology.2019; 44: 1812-1819.
20.
DeaLTranJTsuL. Management of bipolar disorder. US Pharm.2016; 41: 34-37.
21.
IonescuDFLuckenbaughDANiciuMJ. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord.2015; 17: 438-443.
22.
MurroughJWPerezAMPillemerS. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry.2013; 74: 250-256.
23.
VandeVoort JL, MorganRJ, KungS, . Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord.2016; 206: 300-304.
24.
GálvezV, LiA, HugginsC, . Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial. J Psychopharmacol.2018; 32: 397-407.
25.
AlbottCSLimKOForbesMK. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry.2018; 79: 17m11634.
26.
GhasemiMKazemiMHYoosefiA. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res.2014; 215: 355-361.
27.
WilkinsonSTSanacoraG.Considerations on the off-label use of ketamine as a treatment for mood disorders. JAMA.2017; 318: 793-794.
28.
WilkinsonSTToprakMTurnerMS. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry.2017; 174: 695-696.
29.
ShadliSMKaweTMartinD. Ketamine effects on EEG during therapy of treatment-resistant generalized anxiety and social anxiety. Int J Neuropsychopharmacol.2018; 21: 717-724.
30.
GluePNeehoffSMMedlicottNJ. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. J Psychopharmacol.2018; 32: 663-667.
31.
GluePMedlicottNJHarlandS. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol.2017; 31: 1302-1305.
32.
CastleCGrayANeehoffS. Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders. J Psychopharmacol.2017; 31: 1306-1311.
33.
ShiromaPRAlbottCSJohnsB. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol.2014; 17: 1805-1813.
34.
SinghJBFedgchinMDalyEJ. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry.2016; 173: 816-826.
35.
PhillipsJLNorrisSTalbotJ. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry.2019; 176: 401-409.
36.
McIntyreRSRodriguesNBLeeY. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the Canadian Rapid Treatment Center of Excellence. J Affect Disord.2020; 274: 903-910.
37.
McIntyreRSLipsitzORodriguesNB. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disord.2020; 22: 831-840.
38.
WilkinsonSTBallardEDBlochMH. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry.2018; 175: 150-158.
39.
GrunebaumMFGalfalvyHCChooTH. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry.2018; 175: 327-335.
40.
MurroughJWSoleimaniLDeWildeKE. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med.2015; 45: 3571-3580.
41.
GrunebaumM FEllisS PKeilpJG. Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial. Bipolar Disord.2017; 19: 176-183.
42.
DalyEJSinghJBFedgchinM. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry.2018; 75: 139-148.
43.
MoleroPRamos-QuirogaJAMartin-SantosR. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs.2018; 32: 411-420.
44.
HanYChenJZouD. Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat.2016; 12: 2859-2867.
45.
CanusoCSinghJFedgchinM. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized placebo-controlled study. Am J Psychiatry.2018; 175: 620-630.
46.
PopovaVDalyEJTrivediM. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry.2019; 176: 428-438.
47.
PapakostasGISalloumNCHockRS. Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J Clin Psychiatry.2020; 81: 19r12889.
48.
ChenYCJhangJ FHsuYH. Vascular fibrinoid necrosis in the urinary bladder of ketamine abusers: A new finding that may provide a clue to the pathogenesis of ketamine-induced vesicopathy. Low Urin Tract Symptoms.2019; 11: O221-O223.
49.
DuanQWuTYiX. Changes to the bladder epithelial barrier are associated with ketamine-induced cystitis. Exp Ther Med.2017; 14: 2757-2762.
50.
SrirangamSMercerJ.Ketamine bladder syndrome: an important differential diagnosis when assessing a patient with persistent lower urinary tract symptoms. BMJ Case Rep.2012; 2012: bcr2012006447.
51.
LeePOngTChuaC. Street ketamine-associated bladder dysfunction: an emerging health problem. Malays Fam Physician.2009; 4: 15-18.
52.
WanLBLevitchC FPerezAM. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry.2015; 76: 247-252.
53.
RodriguesNBMcIntyreRSLipsitzO. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. Expert Opin Drug Saf.2020; 19: 1031-1040.
54.
ThaseME. Bipolar depression: diagnostic and treatment considerations. Dev Psychopathol.2006; 18: 1213-1230.
55.
SalvadoreGQuirozJAMachado-VieiraR. The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry.2010; 71: 1488-1501.
56.
BanwariGDesaiPPatidarP.Ketamine-induced affective switch in a patient with treatment-resistant depression. Indian J Pharmacol.2015; 47: 454-455.
57.
McInnesLAJames-MyersMBTurnerMS. Possible affective switch associated with intravenous ketamine treatment in a patient with bipolar I disorder. Biol Psychiatry.2016; 79: e71-e72.
58.
MischelNBjerre-RealCKomisarJ. Intravenous ketamine relieves pain and depression after traumatic suicide attempts: a case series. J Clin Psychopharmacol.2018; 38: 149-150.
59.
daFrota Ribeiro CM, SanacoraG, HoffmanR, . The use of ketamine for the treatment of depression in the context of psychotic symptoms: to the editor. Biol Psychiatry.2016; 79: e65-e66.
60.
SanacoraGFryeMAMcDonaldW. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry.2017; 74: 399-405.
61.
MorganCJMuetzelfeldtLCurranH V. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction.2009; 104: 77-87.
62.
MurroughJWWanLBIacovielloB. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology (Berl).2013; 11: 10.1007/ s00213-013-3255-x. doi: 10.1007/s00213-013-3255-x
63.
Sassano-HigginsSBaronDJuarezG. A review of ketamine abuse and diversion. Depress Anxiety.2016; 33: 718-727.
64.
DalyEJTrivediMHJanikA. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry.2019; 76: 893-903.
65.
DiamondPRFarmeryADAtkinsonS. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol.2014; 28: 536-544.
66.
LapidusKALevitchCFPerezAM. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry.2014; 76: 970-976.
67.
SinghJBFedgchinMDalyE. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry.2016; 80: 424-431.
68.
FedgchinMTrivediMDalyEJ. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol.2019; 22: 616-630.
69.
FreemanMPHockRSPapakostasGI. Body mass index as a moderator of treatment response to ketamine for major depression disorder. J Clinical Psychopharmacology.2020; 40: 287-292.
70.
O'BrienB, LijffijtM, WellsA, . The impact of childhood maltreatment on intravenous ketamine outcomes for adult patients with treatment-resistant depression. Pharmaceuticals (Basel).2019:12:133.
